Table 1.
Baseline Demographic and Clinical Characteristics of All Participants
| Characteristics | Healthy control individual (n=100) | Ulcerative colitis patient (n = 70) | Crohn’s disease patient (n = 39) | |
|---|---|---|---|---|
| Age (yr), mean ± SD | 44.1 ± 8.8 | 46.3 ± 14.4 | 35.3 ± 11.7 | |
| Male sex, No. (%) | 54 (54.0) | 44 (62.9) | 30 (76.9) | |
| BMI (kg/m2), mean ± SD | 23.0 ± 3.2 | 23.0 ± 2.8 | 20.7 ± 3.5 | |
| Disease extent (maximum), No. (%) | ||||
| Ulcerative colitis, No. (%) | - | - | ||
| Proctitis | 21 (30.0) | |||
| Left sided colon | 28 (40.0) | |||
| Extensive | 21 (30.0) | |||
| Crohn’s disease, No. (%) | - | - | ||
| Colon | 5 (12.8) | |||
| Small bowel only | 17 (43.6) | |||
| Ileocolon | 17 (43.6) | |||
| Disease severity (maximum), No. (%) | - | |||
| Mild | 37 (52.8) | 6 (15.4) | ||
| Moderate | 16 (22.9) | 6 (15.4) | ||
| Severe | 2 (2.9) | 3 (7.7) | ||
| Remission | 15 (21.4) | 24 (61.5) | ||
| Concomitant drug use, No. (%) | - | |||
| 5-ASA | 70 (100) | - | ||
| Steroid | 1 (1.4) | - | ||
| Azathioprine/6-MP | 9 (12.9) | 29 (74.3) | ||
| Biologic agent | 1 (1.4) | 4 (10.3) | ||
| Previous history of disease-related operations | 0 | 14 (35.9) | ||
SD, standard deviation; BMI, body mass index; 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine.